trial
as of 2026-07-01A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects
NCTId NCT06556966
at a glance
Phase 1 · Completed
Enrollment 66 (actual)
Sponsored by Luye Pharma Group Ltd.
Primary completion 2025-02-13
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 1
Status
Completed
Enrollment
66 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2024-08-19
Primary completion
2025-02-13
Eligibility
ALL · 18 Years · 45 Years
Interventions & indications
Drugs
Sponsors
Luye Pharma Group Ltd.Lead Sponsor
Investigators
1
Gang Wang, MDPrincipal Investigator
Sites
1 total
Beijing, China
Facts & assertions
4 sourced
Enrollment
66
Phase
PHASE1
Primary Completion Date
2025-02-13
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person